G1 Therapeutics Inc

G1 Therapeutics — Investor Presentation (February 2021)

38 slides from G1 Therapeutics's investor presentation, Feb 16, 2021

  1. Slide 1: Optimizing Chemotherapy, Advancing Survival

    Slide 1: Optimizing Chemotherapy, Advancing Survival

    Optimizing Chemotherapy, Advancing Survival February 16, 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events

  3. Slide 3: Transformed Company; Pivotal 2021

    Slide 3: Transformed Company; Pivotal 2021

    Transformed Company; Pivotal 2021 COSELA™ (trilaciclib) CDK2 Discovery Platform Rintodestrant 2021 2020 Pipeline-in-a-molecule development opportunity Rintodestrant + palbociclib Phase 2 data expected 2Q Lerociclib OUT-LICENSED OUT-LICENSED $207M cash on hand (as of December 31, 2020) Streamlined co

  4. Slide 4: Chemo to Remain Mainstay Therapy Despite Shortcomings

    Slide 4: Chemo to Remain Mainstay Therapy Despite Shortcomings

    Chemo to Remain Mainstay Therapy Despite Shortcomings Over 1 million cancer patients receive chemo in North America each year Cost-efficient and effective treatment option expected to remain backbone of SoC Established high water-mark that has proven difficult to exceed head-to-head Immunotherapy wi

  5. Slide 5: COSELA: Novel Approach to Address Shortcomings of Chemo

    Slide 5: COSELA: Novel Approach to Address Shortcomings of Chemo

    COSELA: Novel Approach to Address Shortcomings of Chemo COSELA Transient IV CDK4/6 inhibitor Temporarily blocks progression through the cell cycle Leads to multiple potential downstream effects Protects HSPCs and myeloid and lymphoid cell lineages from damage caused by chemotherapy1-3 Ability to imp

  6. Slide 6: COSELA Demonstrated Meaningful Benefits Across Studies

    Slide 6: COSELA Demonstrated Meaningful Benefits Across Studies

    Myeloprotection Impact1-5 Anti-Tumor Efficacy Impact6-11 Reduced rate of hematologic adverse events (less neutropenia, anemia, thrombocytopenia) Increased patients’ ability to receive longer duration of chemotherapy-based regimens Decreased rescue interventions and costs (less transfusions, G-CSF, h

  7. Slide 7: Significant Expansion Opportunities for COSELA

    Slide 7: Significant Expansion Opportunities for COSELA

    Significant Expansion Opportunities for COSELA Optimizing development plan across three core growth platforms will enable COSELA to benefit as many patients as possible Myeloprotection Improved Survival (single agent) Improved Survival (combinations) Protecting the bone marrow from the damaging cons

  8. Slide 8: Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch

    Slide 8: Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch

    Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch Aggressively pursuing development in areas of high strategic importance where COSELA is most likely to provide meaningful benefits to patients ES-SCLC COSELA Opportunity + Milestones and Royalties Myeloprotection Improved Survival (single agen

  9. Slide 9: 2021 Key Objectives

    Slide 9: 2021 Key Objectives

    2021 Key Objectives Focused on successfully launching COSELA in ES-SCLC and accelerating development into other areas where chemotherapy is used Obtain U.S. approval for ES-SCLC and successfully launch COSELA in 1Q Establish COSELA as Standard of Care for ES-SCLC patients in the U.S. Maximize long-t

  10. Slide 10: 2021 Key Objectives

    Slide 10: 2021 Key Objectives

    2021 Key Objectives Obtain U.S. approval for ES-SCLC and successfully launch COSELA in 1Q Establish COSELA as Standard of Care for ES-SCLC patients in the U.S. Maximize long-term value of COSELA by executing robust development plan Evaluate partnership options for rintodestrant following combination

  11. Slide 11: FDA Approval of COSELA

    Slide 11: FDA Approval of COSELA

    Approved by U.S. Food and Drug Administration to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer

  12. Slide 12: COSELA Efficacy Endpoints and Prescribing Information Highlights

    Slide 12: COSELA Efficacy Endpoints and Prescribing Information Highlights

    Endpoint COSELA 240 mg/m2 (N=54) Placebo (N=53) Adjusted 1‑Sided p‑value Primary Endpoint DSN2 in Cycle 1 - days Mean (SD) 0 (1.0) 4 (4.7) <0.0001 Number (%) of patients with severe neutropenia 1 (1.9%) 26 (49.1%) <0.0001 Key Secondary Endpoints Number of all-cause dose reductions, event rate per cy

  13. Slide 13: COSELA Approved: U.S. Launch in 1Q21

    Slide 13: COSELA Approved: U.S. Launch in 1Q21

    COSELA Approved: U.S. Launch in 1Q21 This important new treatment is available to the majority of patients with ES-SCLC undergoing chemotherapy in the U.S. Label covers a majority of patients Including those treated with I/O Indicated for broad myelosuppression (vs just neutropenia) Multilineage mye

  14. Slide 14: COSELA is Strategically Priced

    Slide 14: COSELA is Strategically Priced

    COSELA is Strategically Priced G1 analyses suggest COSELA pricepoint will enable access in ES-SCLC; expected to be budget-neutral to savings-positive Branded G-CSF* Immunotherapy* ~$25K Per patient (primary prophylaxis) ~$75K per patient ~$34K per patient on average WAC per vial = $1,417 Based on cl

  15. Slide 15: G1 to One: Single Source for Access & Affordability

    Slide 15: G1 to One: Single Source for Access & Affordability

    G1 to One: Single Source for Access & Affordability Benefits investigation Prior authorization and appeals support Out of pocket assistance Access to PAP for therapy for eligible patients Support for patients getting started on COSELA One-stop hub to ensure excellence in COSELA patient support

  16. Slide 16: Opportunity to Meaningfully Impact Many Lives

    Slide 16: Opportunity to Meaningfully Impact Many Lives

    Opportunity to Meaningfully Impact Many Lives Based on incidence of 25k for all SCLC with 81% of patients being diagnosed at Extensive Stage; Decision Resources Group, Small Cell Lung Cancer Disease Landscape & Forecast, March 2020. Based on 22k 1L SCLC total patients (20K de novo ES-SCLC and 2K lat

  17. Slide 17: Three Core Goals for a Successful U.S. ES-SCLC Launch

    Slide 17: Three Core Goals for a Successful U.S. ES-SCLC Launch

    Educate prescribers, payers, and patients on the benefits of COSELA’s proactive multi-lineage protection Gain inclusion into relevant guidelines / pathways; enable broad patient access; and ensure ease of use for prescribers / nurses / staff Increase awareness of the significant multi-lineage impact

  18. Slide 18: Prescribers are Enthusiastic to Use COSELA

    Slide 18: Prescribers are Enthusiastic to Use COSELA

    Prescribers are Enthusiastic to Use COSELA Education will be key to establish COSELA as a Standard of Care for patients with ES-SCLC receiving chemotherapy Prescriber Enthusiasm to Use COSELA for Patients with ES-SCLC Following Education Source: internal market research conducted July 2020 (n=153 on

  19. Slide 19: 2021 Key Objectives

    Slide 19: 2021 Key Objectives

    2021 Key Objectives Obtain U.S. approval for ES-SCLC and successfully launch COSELA in 1Q Establish COSELA as Standard of Care for ES-SCLC patients in the U.S. Maximize long-term value of COSELA by executing robust development plan Evaluate partnership options for rintodestrant following combination

  20. Slide 20: The Burden of Chemotherapy Myelosuppression

    Slide 20: The Burden of Chemotherapy Myelosuppression

    The Burden of Chemotherapy Myelosuppression can have a significant negative impact on clinical outcomes, healthcare costs, and overall patient quality of life An unavoidable consequence of chemo that impacts patient safety, healthcare system costs and QoL MYELOSUPPRESSION Hospitalizations and unsche

  21. Slide 21: COSELA Meaningfully Reduces Myelosuppression in ES-SCLC

    Slide 21: COSELA Meaningfully Reduces Myelosuppression in ES-SCLC

    Reduced Incidence of Multi-lineage Myelosuppression in 1L‒3L ES-SCLC1 (pooled data across our 3 randomized placebo-controlled double-blind trials) Clinical Results: COSELA consistently demonstrated meaningful reductions in hematologic adverse events across multiple randomized ES-SCLC studies P<0.000

  22. Slide 22: COSELA Can Drive Payor/Hospital Savings

    Slide 22: COSELA Can Drive Payor/Hospital Savings

    COSELA Can Drive Payor/Hospital Savings Average total annual cost per patient without a grade 3/4 hematologic event: Average Total Annual Cost Per Patient with a Grade 3/4 Hematologic Event (Jan 2016 – Dec 2019)1 Neutropenia $131,047 Anemia $95,954 Thrombocytopenia $90,053 Payor Impact: COSELA’s abi

  23. Slide 23: Opportunity to Improve Quality of Life with COSELA

    Slide 23: Opportunity to Improve Quality of Life with COSELA

    Opportunity to Improve Quality of Life with COSELA Patient Benefit: Proactive protection enables better quality of life for patients in this palliative treatment setting Epstein et al, Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of

  24. Slide 24: Opportunity for COSELA to Become Standard of Care in ES-SCLC

    Slide 24: Opportunity for COSELA to Become Standard of Care in ES-SCLC

    Opportunity for COSELA to Become Standard of Care in ES-SCLC Heightened awareness of myelosuppression due to the COVID pandemic may further encourage adoption of COSELA as a Standard of Care Clinical Results Meaningfully reduces myelosuppression in ES-SCLC Payer Impact May provide cost savings for s

  25. Slide 25: 2021 Key Objectives

    Slide 25: 2021 Key Objectives

    2021 Key Objectives Obtain U.S. approval for ES-SCLC and successfully launch COSELA in 1Q Establish COSELA as Standard of Care for ES-SCLC patients in the U.S. Maximize long-term value of COSELA by executing robust development plan Evaluate partnership options for rintodestrant following combination

  26. Slide 26: Aggressively Pursuing Development in Common Tumor Types

    Slide 26: Aggressively Pursuing Development in Common Tumor Types

    Aggressively Pursuing Development in Common Tumor Types Estimated new cases and deaths from National Cancer Institute for 2020. Estimated patients receiving chemotherapy from Kantar Health CancerMPact Patient Metrics, 2019 data based on IQVIA BrandImpact regimen shares and Kantar Health Treatment Ar

  27. Slide 27: Broad Portfolio of Studies Across Common Tumor Types

    Slide 27: Broad Portfolio of Studies Across Common Tumor Types

    Broad Portfolio of Studies Across Common Tumor Types Two registrational studies will be ongoing by mid 2021 in addition to multiple Phase 2 studies to evaluate COSELA in several treatment settings / tumor types Cancer Type Indication Study Size Phase 2 Phase 3 Approval Lung ES-SCLC NA 2L / 3L NSCLC

  28. Slide 28: Ongoing First-Line CRC Pivotal Trial

    Slide 28: Ongoing First-Line CRC Pivotal Trial

    Ongoing First-Line CRC Pivotal Trial Cycle X Day 2 Cycle X Day 1 Cycle X Day 2 Cycle X Day 1 Cycle X Day 14 Randomization 1:1 Placebo + CI FU Treatment Phase Placebo + FOLFOXIRI + bevacizumab COSELA + FOLFOXIRI + bevacizumab COSELA + CI FU Induction Phase 14-day cycles Maintenance Phase 14-day cycle

  29. Slide 29: Metastatic TNBC is an Area of High Unmet Need

    Slide 29: Metastatic TNBC is an Area of High Unmet Need

    TNBC tumors categorized by lack of HR expression and HER2 gene amplification Tumors are aggressive and difficult to treat Targeted therapies only demonstrated benefit in subpopulations (e.g., PD-L1 agents, PARPs) Antibody Drug Conjugates (ADCs) demonstrated OS improvement in 3L to date, but have ass

  30. Slide 30: Observed Robust OS Improvement in mTNBC Phase 2

    Slide 30: Observed Robust OS Improvement in mTNBC Phase 2

    Observed Robust OS Improvement in mTNBC Phase 2 Observed a robust statistically significant improvement in Overall Survival for both COSELA schedules Group 1 (gem/carbo)2 Group 3 (COSELA + gem/carbo)2 Group 2 (COSELA + gem/carbo)2 Treatment Group2 Median OS, months Hazard Ratio (95% CI) P Value Grou

  31. Slide 31: OS Improvement Observed, Regardless of PD-L1 Status

    Slide 31: OS Improvement Observed, Regardless of PD-L1 Status

    OS Improvement Observed, Regardless of PD-L1 Status Overall Survival improvement was observed regardless of tumor PD-L1 status (greater effect in PD-L1 positive tumors) Overall Survival for PD-L1 Positive Tumors1 Treatment Group2 Patients Median OS (95% CI), Months Hazard Ratio (95% CI) P Value Grou

  32. Slide 32: Initiating TNBC Phase 3 Trial in 1H 2021

    Slide 32: Initiating TNBC Phase 3 Trial in 1H 2021

    Initiating TNBC Phase 3 Trial (1L and 2L Cohorts) in 1H 2021 Pivotal study evaluating COSELA in mTNBC (PD-L1 positive and negative patients) complements ongoing I-SPY 2 Phase 2 Neoadjuvant BC study GC on Days 1 and 8 every 21 days until progression COSELA + GC on Days 1 and 8 every 21 days until pro

  33. Slide 33: Initiating Two Additional COSELA Phase 2 Trials in 1H 2021

    Slide 33: Initiating Two Additional COSELA Phase 2 Trials in 1H 2021

    Initiating Two Additional COSELA Phase 2 Trials in 1H 2021 Important future expansion areas for COSELA with data available in next 2 – 3 years Strong rationale for COSELA + chemo + I/O in 1L bladder cancer Known immunogenic tumor responsive to chemo + I/O Data suggests synergistic effect of COSELA +

  34. Slide 34: 2021 Key Objectives

    Slide 34: 2021 Key Objectives

    2021 Key Objectives Obtain U.S. approval for ES-SCLC and successfully launch COSELA in 1Q Establish COSELA as Standard of Care for ES-SCLC patients in the U.S. Maximize long-term value of COSELA by executing robust development plan Evaluate partnership options for rintodestrant following combination

  35. Slide 35: Rintodestrant Demonstrated a Favorable Oral SERD Profile in Clinical Trials

    Slide 35: Rintodestrant Demonstrated a Favorable Oral SERD Profile in Clinical Trials

    Rintodestrant Demonstrated a Favorable Oral SERD* Profile in Clinical Trials Next steps will be evaluated following data readout expected in 2Q21 * SERD = Selective Estrogen Receptor Degrader 40-patient Phase 2 combination trial with CDK4/6 inhibitor palbociclib ongoing; data in 2Q21 Phase 2 combina

  36. Slide 36: 2021 Key Objectives

    Slide 36: 2021 Key Objectives

    2021 Key Objectives Obtain U.S. approval for ES-SCLC and successfully launch COSELA in 1Q Establish COSELA as Standard of Care for ES-SCLC patients in the U.S. Maximize long-term value of COSELA by executing robust development plan Evaluate partnership options for rintodestrant following combination

  37. Slide 37: Continue to Efficiently Manage Capital

    Slide 37: Continue to Efficiently Manage Capital

    ~$207M cash at year-end 2020 provides runway into second half of 2022 Efficiently executing plan with lean organization of ~125 FTEs Utilizing capital efficient promotion arrangement with Boehringer Ingelheim for COSELA U.S. launch in SCLC Expect to leverage co-development opportunities with partner

  38. Slide 38: Maximizing Value of COSELA

    Slide 38: Maximizing Value of COSELA

    Maximizing Value of COSELA Expect ES-SCLC launch in 1Q 2021 and multiple data readouts to drive expansion and long-term growth ES-SCLC 1L CRC 2L / 3L NSCLC 1L Bladder Cancer Registrational Trials Phase 2 Trials Other Tumors TBD COSELA Opportunity + Milestones and Royalties Neoadjuvant Breast Cancer

Source: SEC EDGAR · 8-K filed Feb 16, 2021

More decks from G1 Therapeutics Inc